ADVERTISEMENT
ICICI Securities: Strides Pharma’s Q1 Review - Strong Recovery In Growth, Profitability
Minimal capex, healthy operational performance will help Strides Pharma generate free cash flow of Rs 900 crore over FY21-22.
06 Aug 2020, 08:47 PM IST 
A group of multicolored tablets for medical treatment are arranged for a photograph at a pharmacy. (Photographer: Dimas Ardian/Bloomberg)
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
I’m already a Subscriber Sign In
To continue reading this storySubscribe to unlock & enjoy all Members-only benefits
Choose a plan
Renews automatically. Cancel anytime.
As a Subscriber you get
Full Access to
NDTV Profit App
Exclusives
Premium Stories
Access to
Stories
Curated
Newsletters
20,000+
Research Reports
Priority Pass
to Special Events
Minimal Ad
Experience
Members-Only
Rewards
Still Not convinced ? Know More
